DOCSLIB.ORG

Communications Handbook for Clinical Trials

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Communications Handbook for Clinical Trials Communications Handbook for Clinical Trials Clinical Handbook for Communications Communications Handbook for Clinical Trials Communications Handbook for Clinical Trials: Strategies, tips, and tools to manage controversy, convey your Communications message, and disseminate results provides practical guidance to clinical trial staff and research partners on how to anticipate and respond to the special communications challenges posed by the conduct of clinical research. Designed to be accessible and relevant to a wide audience, Communications Handbook for Clinical Trials will make your job easier, whether you are a researcher, a study coordinator, or a communications professional. Handbook The handbook contains diagnostic tools, sample templates, and materials that research sites can adapt for use. n Sample communication plans for clinical trials n Communications and crisis-planning templates and checklists n Scenario-planning tools to facilitate planning for the release of trial results for Clinical Trials n Ideas on delegating communications tasks to reduce demands on key site personnel n Tips and techniques on how to communicate effectively in interviews, in meetings, and with the media Communications Handbook for Clinical Trials contains more than 40 contributed pieces by researchers and communications experts, who share their ideas, lessons learned, and advice based on their experiences with trials in Africa, Asia, Europe, Latin America, and North America. Praise for Communications Handbook for Clinical Trials Strategies, tips, and tools “Too often clinical trial researchers think a clinical trial starts with participant enrollment and closes with the final clinic visit of the last participant, but in fact the life of a trial extends well before and after these points. to manage controversy, This manual addresses all of the things they don’t teach one at university—how to communicate effectively with a range of stakeholders, how to work with the media, and how to build relationships to navigate some of the challenges and unexpected outcomes we encounter all too often in research.” convey your message, and —Prof. Linda-Gail Bekker, Desmond Tutu HIV Foundation, University of Cape Town, South Africa disseminate results “The authors have combined their wealth of communications experience into a lively how-to guide with illustrations from many different fields ... Essential reading for all involved designing or implementing clinical trials, including those who think they know it all.” —Dr. Timothy M. Farley, Department of Reproductive Health and Research, World Health Organization, Geneva By “In an era where research into tangible health-related interventions is a global effort, this handbook represents a Elizabeth T. Robinson thoughtful, well-organized approach to developing communication strategies that address today’s challenges.” Deborah Baron —Dr. Patrick Ndase, Microbicide Trials Network and International Clinical Research Center, University of Lori L. Heise Washington, Kampala, Uganda Jill Moffett Preface written by ARCHBISHOP EMERITUS DESMOND M. TUTU, who is a tireless champion in the fight against Sarah V. Harlan AIDS and tuberculosis, and serves as patron of the Desmond Tutu HIV Foundation and the Desmond Tutu HIV Centre at the University of Cape Town’s Institute of Infectious Disease and Molecular Medicine. Preface by Archbishop Desmond M. Tutu Communications Handbook for Clinical Trials Strategies, tips, and tools to manage controversy, convey your message, and disseminate results By Elizabeth T. Robinson Deborah Baron Lori L. Heise Jill Moffett Sarah V. Harlan Preface by Archbishop Desmond M. Tutu Communications Handbook for Clinical Trials: Strategies, Tips, and Tools to Manage Controversy, Convey Your Message, and Disseminate Results Authors: Elizabeth T. Robinson, Deborah Baron, Lori L. Heise, Jill Moffett, Sarah V. Harlan © Family Health International ISBN: 1-933702-57-5 The handbook is co-published by the Microbicides Media and Communications Initiative, a multi-partner collaboration housed at the Global Campaign for Microbicides at PATH in Washington, DC, and by Family Health International in Research Triangle Park, NC, USA. Global Campaign for Microbicides PATH 1800 K Street NW, Suite 800 Washington, DC 20006 USA Tel: +1.202.822.0033 Web: www.mmci-communications.org www.global-campaign.org Family Health International P.O. Box 13950 Research Triangle Park, NC 27709 USA Tel: +1.919.544.7040 E-mail: [email protected] Web: www.fhi.org This work was made possible by the generous support of the American people through the U.S. Agency for International Development (USAID) through dual grants to the Microbicides Media and Communications Initiative (MMCI), a project of the Global Campaign for Microbicides at PATH, and to Family Health International (FHI). The contents are the responsibility of FHI and do not neces- sarily reflect the views of USAID or the United States Government. Financial assistance was provided to FHI by USAID under the terms of Cooperative Agree- ment GPO-A-00-05-00022-00, the Contraceptive and Reproductive Health Tech- nologies Research and Utilization (CRTU) Program, and Cooperative Agreement GHO-A-00-09-00016-00, the Preventive Technologies Agreement (PTA) Pro- gram, and to PATH by USAID under the terms of Cooperative Agreement GPH- A-00-01-00005-00, the HealthTech IV Program. To request additional copies of the handbook, e-mail: [email protected]. Contents Preface vii Acknowledgments x Chapter One: About This Handbook 1 I. The purpose of this handbook 2 II. Challenges posed by clinical trials 4 III. Origins of the handbook 5 IV. How this handbook is organized 5 Chapter Two: Preparing and Budgeting for Communications 9 I. Doing your homework—a “desk review” 9 II. Conducting an environmental scan 10 III. Developing a communications budget 17 IV. Assembling a communications team 21 V. Training staff and spokespersons 22 Chapter Three: Developing a Strategic Communications Plan 27 I. Background and environmental analysis 27 II. Goals and objectives 29 III. The communications team 29 IV. Identification of key stakeholders 31 V. Strategy for ongoing communication with stakeholders 36 VI. Strategy for managing controversy—crisis communications 38 VII. Dissemination plan for trial results 39 VIII. Materials to support the trial 39 IX. Monitoring and evaluation 42 Chapter Four: Communications During the Trial 45 I. Announcing the start of your trial 45 II. Maintaining good communications 50 III. Tracking and responding to emerging issues 62 IV. Preparing for interim analyses 65 V. Disseminating results 67 Chapter Five: Preventing and Managing a Crisis 69 I. What is a crisis communications plan? 70 II. Why is a crisis communications plan needed? 70 III. Preventing crises 72 IV. Preparing for potential controversy 75 V. Developing a rapid response procedure 78 iii VI. Implementing your crisis communications plan 80 VII. Managing unexpected trial closures 81 Chapter Six: Preparing for and Disseminating Study Results 87 I. The minimum package of dissemination activities 88 II. The dissemination team and plan: compiling the core elements 88 III. Timing, timelines, and time zones 94 IV. Planning for various outcome scenarios 100 V. Managing embargoes and pre-release issues 104 VI. Orchestrating the public announcement 107 VII. Post-announcement dissemination activities 112 Chapter Seven: Developing and Using Key Messages 115 I. Why key messages are important 116 II. How to develop key messages and supporting messages 117 III. Creating tailored messages for any situation 123 IV. Refining and testing your messages 125 V. Delivering key messages 126 Chapter Eight: Communicating Science Clearly 131 I. Why research is necessary 131 II. Translating the language of clinical trials 137 III. Demystifying statistics 143 IV. Five ways to avoid misunderstandings 146 Chapter Nine: Working with the Media 149 I. Understanding the media 149 II. Developing a media strategy 156 III. Responding to media requests 166 IV. Getting your message across 170 V. Being interviewed by the media 172 VI. Helping journalists write good stories 175 VII. Nurturing relationships with the media 177 Appendices Appendix 2.1 A Risk Assessment Tool 180 Appendix 2.2 Microbicide Trials Network: Communications Planning Survey 182 Appendix 2.3 “Thirty Tough Questions” for Trial Staff 190 Appendix 3.1 Sample Strategic Communications Plan 192 Appendix 3.2 “Getting to Know Your Stakeholders” Template 195 Appendix 3.3 Contact List Template 196 Appendix 3.4 Samples of Newsletters for Clinical Trials 197 Appendix 3.5 Sample of Study “Backgrounder” 200 Appendix 3.6 Sample External Questions and Answers (Q&A) 202 Appendix 4.1 Template for a Monthly Summary Report on Communications 205 Appendix 5.1 How Unexpected Closures Can Affect Other Trial Sites: The Cellulose Sulfate Trial Closure in South Africa 207 iv Communications Handbook for Clinical Trials Appendix 5.2 Illustrative Crisis Communications Plan 208 Appendix 6.1 Sample of a Results Dissemination Plan by a South African Site 211 Appendix 6.2 Sample of a Results Dissemination Plan by a Peruvian Site 214 Appendix 6.3 Case Study: Timelines and Tasks for Disseminating the Results of HPTN 035 217 Appendix 6.4 Sample Questions to Include in an Internal Q&A for Trial Results, Based on Three Outcome Scenarios 220 Appendix 6.5 Sample Letter to Ethics Committee Requesting Review of Materials Needed for Dissemination 222 Appendix 6.6 Sample Letter Inviting Community Stakeholders to Learn
Load more

Recommended publications
  • Reducing HIV Infection in Young Women in Southern Africa
    SPOTLIGHT ON PREVENTION Reducing HIV Infection in Young Women in Southern Africa: The Key to Altering Epidemic Trajectories in a Generalized, Hyperendemic Setting Quarraisha Abdool Karim, PhD, and Hilton Humphries, MA The global HIV pandemic has evolved into Communities in Southern Africa1 are burdened a complex mosaic of epidemics within and with the highest HIV prevalence in the world. One between countries, with no single solution for segment of the general population is especially vul- preventing HIV infection. Increasing access to nerable: girls and young women. Some public health antiretroviral treatment has reduced AIDS-related experts now believe that the way to alter epidemic mortality and morbidity rates, but—with nearly trajectories in this region is to use rigorous inter- three million new infections each year—we are los- vention science to create innovative, comprehen- ing the HIV prevention battle (Joint United Nations sive prevention programming that targets girls and Programme on HIV/AIDS [UNAIDS] 2008), primar- young women. ily in sub-Saharan Africa. HIV Infection in Southern Africa For prevention efforts to succeed, prevention pro- Southern Africa is at the epicenter of the global gramming must be tailored to the specific charac- pandemic. Home to less than 1 percent of the teristics of the epidemic that is unfolding in the area global population, it carries a disproportionate to be targeted. Assessing an epidemic at the local or 17 percent of the global burden of HIV infection. regional level is an important first step to enhancing UNAIDS describes the region’s epidemic typology and customizing prevention responses. This requires as a generalized, hyperendemic epidemic charac- a nuanced understanding of who is at highest risk of terized by uniquely high HIV prevalence, ongoing infection and what drives that risk.
    [Show full text]
  • Download 2016
    L’ORÉAL-UNESCO FOR WOMEN IN SCIENCE 2016 INTERNATIONAL AWARDS WOMEN IN SCIENCE have the power to change the world The L’Oréal-UNESCO For Women in Science programme was founded in 1998 with a simple aim; to ensure that women are fairly represented at all levels in science. We face unprecedented challenges in our world; climate change, sustainable energy, affordable healthcare, security among other issues. Part of the solutions will come from science and science needs women. Those recognized by the L’Oréal-UNESCO programme have already proved how transformative their science can be in addressing these challenges. Science is indeed part of the future, and it needs every talented mind available, be they men or women. The L’Oréal-UNESCO For Women in Science programme aims to ensure that research in every field takes full advantage of the intelligence, creativity and passion of one-half of the population of the planet. The world needs science, science needs women because women in science have the power to change the world. Isabel Marey Semper General Manager L’Oréal Foundation WOMEN IN SCIENCE have the power to change the world Gender equality is a global priority for UNESCO. In general, the situation for women and girls in terms of access to education, especially higher education, career progression and participation in decision making processes, remains a matter of concern. As ‘UNESCO Science Report: towards 2030’ shows, the disparity is particularly evident in the natural sciences where the number of women participating in science still lags behind in many areas like the physical sciences and engineering.
    [Show full text]
  • Nelson R Mandela School of Medicine, University of Natal, Private Bag X7, Congella 4013, Durban
    Doris Duke Medical Research Institute (2nd Floor), University of KwaZulu-Natal, 719 Umbilo Road / (Private Bag X7) Congella, 4013, Durban, South Africa Tel: +27-31-260 4555 Fax: +27-31-260 4549 E-mail: [email protected] MEDIA STATEMENT ISSUED BY: The Centre for the AIDS Programme of Research in South Africa (CAPRISA) STRICTLY EMBARGOED UNTIL TUESDAY, 24 FEBRUARY 2015, 12h15 (US SEATTLE) and 22h15 (SOUTH AFRICA) New tenofovir gel study shows no effect on HIV prevention: Lower than expected gel use impact FACTS trial results 24 February 2015 – HIV prevention for women suffered a setback today when a study conducted by the Follow-on African Consortium for Tenofovir Studies (FACTS) reported that its results do not confirm the HIV protective effect of tenofovir gel shown previously in the CAPRISA 004 trial. The FACTS 001 trial involving 2059 South African women showed no overall HIV prevention benefit of the gel. However, a sub-group analysis based on gel use confirmed by tenofovir detection in genital fluid, showed a 52% reduction in HIV infection. The CAPRISA study had reported in 2010 that tenofovir, applied as a gel before and after sex, reduced HIV infection by 39% overall and by 54% in women who used the gel consistently. CAPRISA is an official research institute of the The results of the FACTS 001 study, which was led by Professors Helen Rees and University of KwaZulu- Natal and Columbia Glenda Gray, were markedly influenced by the large proportion of women who did University. not apply the gel consistently. This is similar to the experiences in the VOICE CAPRISA was (Vaginal and Oral Interventions to Control the Epidemic) trial involving women from established in 2002 through a CIPRA grant Uganda, South Africa and Zimbabwe.
    [Show full text]
  • Country-Specific Factors That Compel South African Scientists to Engage
    COMMUNICATING SCIENCE ACROSS CULTURES, COMMENTARIES FROM SESSIONS AT PCST2018 Country-specific factors that compel South African scientists to engage with public audiences Marina Joubert Abstract A study in South Africa shed light on a set of factors, specific to this country, that compel South African scientists towards public engagement. It highlights the importance of history, politics, culture and socio-economic conditions in influencing scientists’ willingness to engage with lay audiences. These factors have largely been overlooked in studies of scientists’ public communication behaviours. Keywords Public engagement with science and technology; Science communication in the developing world DOI https://doi.org/10.22323/2.17040304 Introduction Science communication scholars increasingly recognise the importance of understanding the factors that motivate or constrain scientists in terms of their participation in science engagement [e.g. Davies, 2008; Rödder, 2012; Searle, 2013; Peters, 2014; Dudo and Besley, 2016]. Factors such as field of research, career stage, age and gender have been explored comprehensively [e.g. The Royal Society, 2006; Dunwoody, Brossard and Dudo, 2009; Bauer and Jensen, 2011; Bentley and Kyvik, 2011; Crettaz von Roten, 2011; Ecklund, James and Lincoln, 2012; Dudo, 2013; Peters, 2013; Johnson, Ecklund and Lincoln, 2014; TNS-BMRB, 2015; Chikoore et al., 2016]. Studies have focused on scientists’ interactions with journalists [e.g. Peters, 2013] and the impact of new media [e.g. Peters et al., 2014], or documented how scientists’ interactions with the public are influenced by the institutions where they work [e.g. Jacobson, Butterill and Goering, 2004; Grand et al., 2015; Marcinkowski et al., 2014] or their attitudes towards communication and the public [e.g.
    [Show full text]
  • What Can We Learn from the HIV Response About Pandemic Preparedness for SARS-Cov-2 and Beyond
    What can we learn from the HIV response about pandemic preparedness for SARS-CoV-2 and beyond CLASS SESSIONS Dates: June 7 and 8, 2021 Time : 8:30am to 12:30pm Location: TBD/Zoom INSTRUCTORS Salim S Abdool Karim [email protected] / [email protected] Quarraisha Abdool Karim qa4@cumc. columbia.edu / [email protected] Course Description The SARS-CoV-2 pandemic is the most recent and challenging pandemic facing humanity in the 21st century. Country responses to this 2020 pandemic provide important insights on retuns on public health investments made in response to the HIV pandemic but also shaped by political leadership and the balance or prioritisation of saving lives, livelihoods and viral suppression. The role of science and knowledge generation has been unprecedented including the development of several efficacious vaccines. The emergence of new variants of concern of SARS-CoV-2 even as SARS-CoV-2 vaccines are being rolled out across the globe; continued high rates of infections and deaths underscore our inter-dependence and the many research questions that remain unanswered. Global responses to the HIV pandemic have important lessons for responses to SARS-CoV-2. This interactive course will share lessons learnt from responses to SARS-CoV-2 including its interaction with HIV and what lessons our HIV response has for responding to SARS-CoV-2. Course Objectives By the end of the course, students will have a greater appreciation of key elements of an effective response to SARS-CoV-2; the interaction between SARS-CoV-2 and HIV; and lessons from HIV for SARS-CoV-2.
    [Show full text]
  • HIV Risk Associated with Serum Medroxyprogesterone Acetate (MPA) Levels Among Women in East and Southern Africa: a Case- Control Study
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author AIDS. Author Manuscript Author manuscript; Manuscript Author available in PMC 2020 March 15. Published in final edited form as: AIDS. 2019 March 15; 33(4): 735–744. doi:10.1097/QAD.0000000000002123. HIV risk associated with serum medroxyprogesterone acetate (MPA) levels among women in East and southern Africa: a case- control study Renee Heffron, University of Washington Randy Stalter, University of Washington Maria Pyra, University of Washington Corresponding author: Renee Heffron, 325 Ninth Avenue Box 359927, Seattle, WA 98104, [email protected], P: 206-520-3800, F: 206-530-3831. Author contributions RH and JMB conceived the study. RH wrote the first draft of the manuscript. RH, RS, and MP performed statistical analyses. JMB and JRL were awarded grant to fund the study. DWE and SWB oversaw laboratory technicians that performed analyses of progestin quantification. NM led site teams that collected the data. All authors contributed critical revisions to the analysis and interpretation and reviewed the final manuscript draft. Conflicts of Interest JMB is on an Advisory Committee of Gilead Sciences. All other authors declare no conflicts of interest. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Partners in Prevention HSV/HIV Transmission Study Team University of Washington Coordinating Center and Central Laboratories, Seattle, USA: Connie Celum (principal investigator), Anna Wald (protocol co-chair), Jairam Lingappa (medical director), Jared M. Baeten, Mary Campbell, Lawrence Corey, Robert W. Coombs, James P. Hughes, Amalia Magaret, M.
    [Show full text]
  • Samrcnewsletteraug2021.Pdf
    Building a healthy nation through research,NEWS innovation and transformation AUGUST 2021 WE ARE NOT SAFE UNTIL WE ARE ALL SAFE SOUTH AFRICAN MEDICAL RESEARCH COUNCIL OUR SCIENCE AT A GLANCE OUR SCIENCE AT A GLANCE Leading research and innovation in a Emerging Research and Practice on time of COVID-19 GBV in the time of COVID-19 While South Africa and the rest of the world continue to GHRU, led the development of the second GBV Strategy for confront the COVID-19 pandemic, there has been concern the Solidarity Fund (funded by the Bill and Melinda Gates of an upsurge in gender-based violence (GBV), particularly Foundation). Dr Shai provided expert advice to the Fund Since the start of COVID-19, the South African Medical foundation for enhanced infection control practices in during the lockdown. Reiterating our indelible mark in the to develop a Theory of Change and identify sustainable Research Council (SAMRC) has been responsive to healthcare settings, contributed to community surveillance country’s ongoing fight against GBV, we have led research solutions, while leading the stakeholder consultations to change, leading research and dialogue on the pandemic. initiatives and improved understanding of the pandemic in and dialogue in trying to understand what has happened prioritise the strategic focus areas and identified solutions. We also continued with pioneering cutting-edge medical South Africa. and make further strides to preventing women and girls innovations and programmes to support the South African from being exposed to GBV. This culminated into the allocation and provision of Government’s response to the pandemic to improve the R75 million in funding through a nation-wide Call for quality of life and health status of people in South Africa.
    [Show full text]
  • Faculty News Fourth Quarter 2014
    Faculty of Health Sciences, University of Cape Town Faculty News Fourth Quarter 2014 Undergraduate students celebrate at annual results bash p.3 highlights Final years rock graduation and Milestone anniversaries celebrated Prestigious awards to staff and 2014 3-5 excel once again 6-7 by IDM and Lung Institute 8-9 Ad-hominem promotions announced Preventing violence against High-level EU visit to HIV clinical Health and healthcare 20 years 11 trial sites launches EDCTP11 children – breaking the 15 16 after Mandela – Dean’s Forum funding intergenerational cycle Dean’s corner Dear colleagues A motion carried in Parliament, with a letter from the Speaker of Parliament, Baleka Mbete, to congratulate us on being the top faculty of health sciences in Africa – what a way to end our year! As always, our last quarter is our busiest as years of hard work bear fruit - evident from the announcements of academic achievements for both students and staff. This year has been no exception. I am absolutely delighted with recent announcements of several premier scholarly awards – from life-time achievements at the 2014 MRC Awards ceremony (Professors Robin Wood and Gregory Hussey); Fellows of UCT (Professors Gregory Hussey and Naomi Levitt) and recognition of teaching excellence (Prof Del Khan) to Rhodes scholarships at Oxford for three of our medical graduates (new graduates Dr Tinashe Chanauka and Dr Jessica Posel Price, and alumnus Dr Alex von Klemperer). This is the second year running, in my 18 months at UCT, that I have the honour of celebrating such prestigious levels of achievement within the Faculty.
    [Show full text]
  • Brief Bio Quarraisha Abdool Karim, Phd Quarraisha Abdool Karim, Phd
    Brief Bio Quarraisha Abdool Karim, PhD Quarraisha Abdool Karim, PhD, is an infectious diseases epidemiologist, who’s main research focuses are on understanding the evolving HIV epidemic in South Africa; factors influencing acquisition of HIV infection in adolescent girls; and sustainable strategies to introduce ART in resource-constrained settings. She is the Associate Scientific Director of CAPRISA, Professor of Epidemiology at the Mailman School of Public Health, Columbia University and Adjunct Professor in Public Health at the Nelson R Mandela School of Medicine, University of KwaZulu-Natal, South Africa. Her most important scientific contribution to HIV prevention is the CAPRISA 004 tenofovir gel trial which demonstrated effectiveness of coitally-applied tenofovir gel in preventing HIV and HSV-2 acquisition in women. She is the Principal Investigator of the CAPRISA 008 tenofovir gel implementation effectiveness trial. Further, her research on HIV epidemiology in young women has been widely utilized in developing responses to the HIV epidemic in southern Africa. She was part of the team, initially as its leader, that conducted the SAPiT trial on TB-HIV treatment, which has shaped international treatment guidelines on the clinical management of co-infected patients. In terms of policy and implementation, she currently chairs the SANAC Prevention Technical Task Team, which draws upon her past experience in establishing South Africa’s National AIDS and STD Programme in 1995. She is the Vice President for the African Academy of Science, Southern Africa, and Foreign Associate Member of the Institute of Medicine (IoM) of the National Academies. She has been the recipient of several international and national awards for her scientific contributions, including the Order of Mapungubwe, bronze, for outstanding work in the field of HIV/AIDS and TB research, and health policy development.
    [Show full text]
  • Engagement of AAS Fellows and Affiliates in 2019
    Engagement of AAS Fellows and Affiliates in 2019 We give special thanks to Fellows and Affiliates who have advanced the work of the Academy by being involved in the delivery of these African Academy of Sciences activities: The AAS Scientific Working Groups The AAS has 18 Scientific Working Groups (SWGs) that are made up of Fellows of the AAS who serve as Chars and members of these groups. The groups advice on global and regional trends within their disciplines/thematic areas, lead discussions and/or advise the AAS on topical issues affecting or that could affect the continent, write policy briefs, assist the AAS to come up with strategies for the application of emerging technologies among other roles. African Synchotron Initiative Malik Maaza Paco Sereme South Africa Burkina Faso Chair Physical Sciences Agricultural and Nutritional Shabaan Khalil Sciences Egypt Agriculture Physical Sciences Mary Abukutsa-Onyango Chair Kenya Mohamed Mostafa El-Fouly Agricultural and Nutritional Members Egypt Sciences Paul-Kingsley Buah-Bassuah Agricultural and Nutritional Sciences Ghana Bassirou Bonfoh Physical Sciences Members Togo Kadambot Siddique Agricultural and Nutritional Australia Sossina Haile Sciences Ethiopia & United States of America Agricultural and Nutritional Sciences Engineering Technology and Applied Thameur Chaibi Mohamed Sciences Oluyede Ajayi Tunisia Nigeria Geological, Environmental, Earth Agricultural and Nutritional Sciences Simon Connell and Space Sciences South Africa Anthony Youdeowei Akiça Bahri Physical Sciences Nigeria Tunisia
    [Show full text]
  • SOUTH AFRICAN MEDICAL RESEARCH COUNCIL: MOVING FORWARDS MRC President, Professor Glenda Gray 18 August 2014 16H00 – 17H30
    SEMINAR INVITATION SOUTH AFRICAN MEDICAL RESEARCH COUNCIL: MOVING FORWARDS MRC President, Professor Glenda Gray 18 August 2014 16h00 – 17h30 Including FRC Young Investigators Best Publication 2013 Awards Refreshments to follow Wolfson Pavilion Lecture Theatre, UCT Medical Campus The Dean of the University of Cape Town’s Faculty of Health Sciences, Professor Wim de Villiers, invites you to attend a presentation from the new President of the South African MRC, Professor Glenda Gray, on the plans for the MRC moving forwards. Glenda Gray, MBBCH, FCPaeds (SA), DSc (honoris causa), an NRF A rated scientist, is the President of the South African Medical Research Council (MRC). Gray, who trained as a Medical Doctor and Paediatrician at the University of the Witwatersrand, co-founded and led the internationally renowned Perinatal HIV Research Unit, based at the Chris Hani Baragwanath Hospital in Soweto. She has expertise in mother to child transmission of HIV, HIV vaccines and microbicides. She is the Co-PI of the HIV Vaccine Trials Network and Director of the HVTN International Programs. In 2002, she was awarded the Nelson Mandela Health and Human Rights Award for pioneering work done in the field of Mother-to-Child Transmission of HIV-1. She is a member of the Academy of Science in South Africa, and chairs their standing committee on health. She is a member of the Institute of Medicine, of the National Academies, and serves on their Global Health Board. Gray has also been awarded the IAPAC “Hero of Medicine” award for work done in the field of HIV treatment in children and adults.
    [Show full text]
  • Quarraisha Abdool Karim Wins Twas-Lenovo Prize
    QUARRAISHA ABDOOL KARIM WINS TWAS-LENOVO PRIZE South African scientist named winner of TWAS's most prestigious award for commitment to life-saving research that protects African women from HIV/AIDS MUSCAT, Sultanate of Oman – South African epidemiologist Quarraisha Abdool Karim was named winner of the 2014 TWAS-Lenovo Science Prize Sunday for her life-saving research into medical and social strategies against HIV and AIDS. The award, one of the most prestigious honours given to scientists from the developing world, was announced here in a special ceremony during the yearly General Meeting of The World Academy of Sciences (TWAS). Abdool Karim's work focuses on a topical anti-HIV gel that appears to dramatically reduce HIV infection, while giving women direct, effective control over their health. The annual prize includes an award of USD100,000 provided by Lenovo, the global leader in consumer, commercial, and enterprise technology that is the largest PC company in the world. "We have a great admiration and respect for the work of Dr. Abdool Karim," said TWAS President Bai Chunli. "She has an exemplary record of high-impact science, and there is a deep humanity to her work. Just as important, she has helped to train hundreds of young African scientists who are expanding the research into HIV and tuberculosis. She really is a model scientist, and a tremendous inspiration to colleagues across the world." "Innovation is how Lenovo achieves competitive differentiation and drives new market opportunities. Lenovo's global scale and emphasis on innovation give us a degree of visibility regarding the health and well-being of the communities and markets we serve," said Yuanqing Yang, Chairman & CEO of Lenovo.
    [Show full text]